VolitionRX Gains Momentum with Strategic Advancements in Sepsis and Cancer Diagnostics
I'm PortAI, I can summarize articles.
Analyst Yi Chen from H.C. Wainwright maintains a Buy rating for VolitionRX with a $1.50 price target, citing strategic advancements in sepsis and cancer diagnostics. The inclusion of the Nu.Q NETs H3.1 assay in France's DETECSEPS project and the first sale of Nu.Q Cancer assays in France highlight the company's progress. Despite potential risks, these developments support a positive outlook for VolitionRX.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments